Mixing two peptides in one syringe: what the chemistry says

WOLVERINE (BPC-157 + TB-500)regeneration

The Wolverine Stack: BPC-157 + TB-500 in equal parts in one vial (50/50: 10mg = 5mg each, 20mg = 10mg each). The most researched healing peptide duo for tissue repair, tendon recovery, and systemic regeneration. Batch-specific Janoshik COA.

CJC-1295 (No-DAC)/Ipamorelingrowth

2-in-1 growth hormone blend: CJC-1295 no-DAC (Modified GRF 1-29, 5 mg) + Ipamorelin (5 mg) combined in one vial. The CJC-1295 component is the short-acting no-DAC variant (about 30 minute half-life), not the long-acting DAC form. Stimulates natural GH release through two different pathways for amplified, more physiological growth hormone pulses.

Semax/Selankcognitive

Pre-mixed combination of the two leading nootropic peptides in one vial. Semax boosts focus and BDNF, Selank reduces anxiety and enhances calm. Together they provide balanced cognitive enhancement for research.

Accessoriesaccessories

Bacteriostatic water and research supplies

This question comes up regularly in research forums: can you draw up two peptides together in one syringe instead of working twice? How often exactly, we counted, more on that shortly. What stands out in the answers we read along the way is how rarely a source is attached. This article approaches the question from the chemistry, with evidence, and explicitly names where the evidence is missing.

For context up front: this text addresses the behavior of peptides in solution and handling in the lab. It is not a usage, dosing, or injection guide, and it should not be read as one. All our products are intended exclusively for laboratory research.

What is actually being asked

So as not to write past the question, we measured it first. From five relevant research subreddits we captured all posts over one year, from August 5, 2025 to August 5, 2026, a total of 95,262 posts, and matched them against 21 search terms related to mixing. 942 posts contain at least one of these, and in 233 of them two or more specific peptides are named together.

This is our own analysis, not a citable research finding. Method, data source, and limitations are listed as source 43 at the end of this article. These numbers measure which questions are being asked, and say nothing about what happens chemically.

These pairs occur together most often:

Two things stand out. First, GHK-Cu appears in five of the nine most frequent pairs, even though it is not the most discussed peptide overall: in the mixing context it is the second most frequent, with 120 posts. Second, the three most frequent pairs are all combinations that also exist as ready-made blends: BPC-157 with TB-500 as its own blend, and the two GHK-Cu pairs as part of GLOW (GHK-Cu, BPC-157, TB-500) and KLOW (the same three plus KPV) respectively. So the community discusses exactly the combinations that are offered as pre-mixed blends, which can be read in both directions: as confirmation by the market, or as an offer that raises the question in the first place.

In posts that name a motive, the number of daily injections with extensive combinations is cited, not a chemical consideration. A second motive appears with the copper peptides: the assumption that adding other peptides eases the burning sensation on injection. How widespread each of these two motives is, we did not count.

Named as problems, in this order: burning or stinging (37 posts), concern about contaminating the vial (28), precipitation (27), turbidity (24), gel formation (18), clumping (15), and visible particles (14).

One case deserves close attention. Among the 20 joint mentions of MOTS-c together with retatrutide, there is one explicit first-hand account: the author reportedly drew up both substances together to save syringes, the mixture reportedly turned milky white and clumped, and they warn others against it. This is a single case without a photo, without a batch reference, and without laboratory testing, so it is not evidence for a chemical rule. It is, however, evidence that the question is being asked and that something visible happened at least once. A published investigation of this pair does not exist; we searched for one.

The question is not whether the peptides get along

An obvious mistake in thinking is to treat the question as a relationship between two active ingredients, as though molecules could get along with each other or not. In fact, when mixing two ready-made solutions, you are not drawing together two peptides, but two complete formulations: in each case a peptide, a solvent, its pH, its salt content, and its preservative.

How different these environments can be is already evident from a look at approved drugs of the same substance classes. The GLP-1 class is formulated nearly neutral: Ozempic at about pH 7.4, Mounjaro and Zepbound in the range of 6.5 to 7.5. The approved amylin analog Symlin, by contrast, sits at about pH 4.0, and Increlex, the sequence-identical IGF-1 preparation, at about pH 5.4 in an acetate buffer. That is three orders of magnitude difference in proton concentration between preparations that all contain peptides.

That is why on every product page we provide a classification into three solvent regimes: nearly neutral bacteriostatic water, a dilute acidic dilution, and the copper peptides, which are dissolved nearly neutral and explicitly not acidified. The full table with the corresponding sources is in our guide Why does my peptide turn cloudy.

Which combinations cross which regimes

This at least allows the question to be organized for the combinations actually discussed. Organized, not answered. The table shows exactly one thing: whether our classification shows a switch between the acidic and the nearly neutral regime. It permits no more than that, and no less either.

Three caveats, so this table is not misread.

First: same regime does not mean same pH. Bacteriostatic water is specified under USP at pH 5.7 within a range of 4.5 to 7.0, and even the approved tesamorelin preparation is set to a range of 4.5 to 7.4. Two peptides that are both classified as nearly neutral can therefore very well have different starting pH values and different buffer capacities. The table only shows that the classification does not indicate a switch between acidic and neutral regime.

Second: the classification itself is documented to varying degrees. For the GLP-1 class and for IGF-1, approved preparations exist with a pH stated in the prescribing information. For many others, including MOTS-c, SS-31, NAD+, KPV, Selank, and Semax, no official specification exists; there, the classification is simply the usual handling with standard water, not a documented substance property. Which row rests on which source is made transparent by the table in the article Why does my peptide turn cloudy.

Third: no regime switch is not a clearance. pH is only one of several possible sources of error; concentration, ionic strength, preservative, and possible interactions of the molecules themselves remain untested in every case. For not a single row of this table does a published compatibility study exist.

MOTS-clongevity

Mitochondrial-derived signaling peptide (16 amino acids) that mimics the effects of exercise at the cellular level. Activates AMPK, improves glucose uptake, and enhances fat metabolism - a key tool in metabolic and longevity research.

NAD+longevity

Essential cellular coenzyme that declines with age. Powers energy metabolism in every cell, activates sirtuins (longevity genes), and supports DNA repair. A cornerstone molecule in aging and longevity research.

What actually changes when two solutions are combined

Three variables can change at the same time as soon as two solutions end up in one container, and all three govern solubility. If both solutions are buffered similarly, the pH can remain largely unchanged; if the regimes differ, it shifts.

pH and the solubility minimum

Peptides and proteins are least soluble where their net charge approaches zero, because the molecules then no longer repel each other electrically. However, this minimum does not have to coincide with the isoelectric point. In recombinant human tissue factor pathway inhibitor, an inverted bell-shaped solubility profile was measured with a broad minimum between pH 5 and 10, the center of which lay two to three pH units away from the isoelectric point. Whether this pattern transfers to arbitrary peptides is not shown by this single study. It does show, however, that the assumption that it suffices to avoid the isoelectric point does not hold true for at least one investigated molecule.

Concentration and ionic strength

Combining is always also diluting and always also mixing salts. In a therapeutic antibody it was shown that solubility does not simply rise or fall with salt concentration, but behaves non-monotonically and additionally depends on the type of anion: first a decrease, then an increase with rising ionic strength. In recombinant interleukin-1 receptor antagonist, low ionic strength accelerated aggregation, but only in the high-concentration range of 50 to 100 mg/ml. Below 1 mg/ml, no conformational changes were measured across the tested ionic strength range, which is something different from proof that no aggregation occurs there.

The preservative in the water

Bacteriostatic water is not just water. It contains 0.9 percent benzyl alcohol, and benzyl alcohol is a pharmaceutically well-studied substance with two faces.

On one side: in a 1997 Genentech study, exactly this concentration of 0.9 percent benzyl alcohol altered the near-UV circular dichroism spectrum of recombinant interferon-gamma, which corresponds to tertiary structure, while the far-UV spectrum, and thus secondary structure, remained unchanged. High-molecular-weight aggregates formed alongside this. A later study ranked benzyl alcohol among preservatives: m-cresol has a stronger aggregation-promoting effect, then phenol, then benzyl alcohol, then phenoxyethanol. Benzyl alcohol is thus the milder preservative in this ranking, not the most aggressive.

On the other side: in a 31-amino-acid acylated peptide, benzyl alcohol triggered no detectable aggregation and no measurable interaction whatsoever in the NMR experiment, while 1 percent m-cresol on the same peptide caused a quarter of the substance to precipitate as insoluble aggregates after 24 hours. Approval practice also argues against demonizing benzyl alcohol across the board: the approved GHRH analog Egrifta WR is explicitly reconstituted exclusively with bacteriostatic water, as is Serostim in the 4 mg strength, which may then be stored refrigerated for 14 days, and Increlex contains 9 mg of benzyl alcohol per milliliter directly in the ready-to-use solution.

The special case of copper peptides: an open question, not a warning

GHK-Cu is a copper complex, and the blends KLOW and GLOW contain this complex. Copper is a redox-active metal. This makes it the most interesting case and, at the same time, the most poorly documented one. We therefore only lay out here, side by side, what is documented and what is not.

Documented: the tripeptide GHK binds copper(II) tightly enough to compete with albumin for the metal at pH 7.5; at equal molar amounts, about 42 percent of the copper was bound to the peptide in an equilibrium dialysis. The coordination geometry of this complex is itself pH-dependent: the amino group of the lysine only participates in the alkaline range, and is protonated at physiological pH. The free tripeptide GHK, meaning the ligand without the copper, remained stable in a preformulation study in water and in buffers from pH 4.5 to 7.4 for at least two weeks at 60 degrees; the same study explicitly names oxidative stress as a separate degradation pathway, independent of pH. This result cannot simply be carried over to the finished copper complex; we found no corresponding study on the complex itself.

Also documented: copper(II), together with hydrogen peroxide or ascorbate, can oxidize the side chains of methionine, histidine, phenylalanine, tryptophan, and tyrosine. In interferon beta-1a this led to covalent cross-links and aggregates, and in model peptides to histidine-histidine bridges, with adjacent histidines being markedly more susceptible than isolated ones.

What, by contrast, is documented nowhere: we searched specifically and found no study examining the actual everyday case, namely two research peptides together in a refrigerated container for a short time, without added hydrogen peroxide and without ascorbate. All the oxidation studies we found add these reaction partners, and some work at elevated temperature and over hours. So the mechanism is documented; its transferability to a syringe is not.

One observation on this that is fair in both directions: of the peptides most frequently mentioned together with copper peptides in the community, BPC-157 and KPV, according to the structural data in PubChem, carry none of the side chains identified as attack points in these oxidation studies. Neither sulfur nor histidine, tryptophan, or tyrosine. This is our own analysis of published structural data, not a statement from a publication, and it does not substitute for testing.

Looking clear is the weakest of all tests

A rule of thumb states: if it stays clear, it is fine. What a clear solution actually rules out is visible precipitation. It does not prove compatibility.

The pharmacopoeia test for parenterals up to 100 ml is considered passed if, on average, no more than 6,000 particles of 10 micrometers or larger and no more than 600 particles of 25 micrometers or larger are present per container. A solution may therefore contain considerable amounts of particles and still be compliant, long before anything becomes visible. Even between instrumental methods there are worlds of difference: micro-flow imaging found markedly more particles in a protein solution than light obscuration, because it also captures non-spherical particles and ones whose refractive index resembles that of the solvent. If the standard method already overlooks particles that another instrument finds, then the eye is not the final authority.

This is how physical compatibility is actually determined: in one methods paper, eight methods were compared side by side, including light obscuration, turbidimetry, dynamic light scattering, zeta potential, light microscopy, and pH measurement, with the result that only a combination of several methods reliably indicates incompatibility. A recent method-stratified review for intensive care medicine evaluated 4,465 drug pairs: 43.94 percent were compatible, 8.24 percent incompatible, and for 45.29 percent there was simply no usable data. So in hospital pharmacy, with systematic methodology and decades of literature, almost half of all pairings remain unresolved.

What the insulin rules show

For insulin, mixing rules have been officially regulated for decades. Looking there is worthwhile because it shows what a robust compatibility statement looks like: narrow, specific, and conditional.

Insulin glargine, which is formulated at about pH 4, carries an unconditional prohibition in the prescribing information against mixing with any other insulin or any other solution. Insulin lispro may be mixed exclusively with NPH insulin, must be drawn up first in that combination, and injection must follow immediately after mixing; in pump use, any mixing is prohibited. The same structure applies to human insulin: only with the one named partner, clear solution first.

That these rules are not theoretical is shown by a 1987 HPLC study: when soluble insulin was drawn up together with isophane or zinc insulin in the same syringe, a substantial portion of the soluble insulin disappeared from solution within minutes, often more than half in under two minutes, depending on the mixing ratio. Two preparations stable on their own, unstable within minutes in one syringe. A second example from a completely different field points in the same direction: bevacizumab drawn up and stored together with triamcinolone acetonide in one syringe showed 28.4 percent degradation after 48 hours, versus 9.6 percent in the control.

Both examples share the same limitation, and it belongs here: in each case, the partner was not a clear solution but a suspension. Isophane and zinc insulin are suspensions, as is triamcinolone acetonide. So they demonstrate that drawing up two ready-made preparations together can go wrong quickly and measurably, not specifically the case of two clear peptide solutions.

And it does not stop with insulin. The approved amylin analog pramlintide, brand name Symlin, is itself a peptide and carries an explicit prohibition on mixing: it must not be mixed with any type of insulin, and both must always be given as separate injections. The justification is noteworthy because it is measured, not inferred. The prescribing information cites as the reason that mixing alters the pharmacokinetics of both products, and relies on a comparison in which pramlintide premixed together with various insulins in one syringe was tested against the same substances given as separate injections. Pramlintide is also the approved relative of cagrilintide, which we carry. Exactly this study, premixed versus separate, is missing for every pair of research peptides.

The point is not that research peptides behave like insulin. The point is the standard: wherever mixing is permitted at all, it is permitted with a sequence and a time limit, and that after decades of testing. For our peptides, none of that exists.

Why a pre-mixed blend is something different from a self-mixed one

There are approved drugs that contain two peptides in one solution. They are the best available evidence that a joint formulation is its own development effort, not simply pouring things together.

Xultophy combines insulin degludec with liraglutide and is formulated at about pH 8.15. That is exactly the pH of the liraglutide single-agent preparation Victoza, whereas the degludec single-agent preparation Tresiba sits at 7.6. So the combination adopted the pH of one of the two partners rather than forming an average; why the choice turned out that way is not stated in the documents we reviewed. The European assessment report describes the selection of preservative, tonicity agent, and stabilizer, as well as the pH adjustment, as its own development step. It becomes even clearer with Soliqua, the combination of insulin glargine and lixisenatide at pH 4.5: there, zinc stabilizes the glargine and methionine stabilizes the lixisenatide. Each of the two partners gets its own stabilizer.

How concrete this problem becomes as soon as two peptides from different regimes are supposed to go together is shown by a 2024 Novo Nordisk patent application. It describes a liquid co-formulation of an amylin receptor agonist and a GLP-1 receptor agonist, and names the obstacle explicitly: the isoelectric point of the GLP-1 agonist rules out co-formulation in exactly the pH range where the amylin agonist is chemically stable. The application states computationally predicted isoelectric points for this purpose, among them about 4.03 for tirzepatide and about 3.93 for retatrutide, versus 7.6 to 9.4 for the amylin agonist, and proposes a cyclodextrin, among other things, as a solution. Three qualifications belong here. This is a patent application, not a peer-reviewed publication. The pI values stated are calculated, not measured. And the formulation examples actually described concern cagrilintide with semaglutide; retatrutide is mentioned there only generically as a representative of the drug class and in the list of calculated pI values, and the application does not show a need for the cyclodextrin specifically for retatrutide. The underlying idea remains notable: a pharmaceutical company needs an additional excipient and a patent application for two peptides from different pH regimes.

That two peptides in one shared liquid can be a real problem is shown by a formulation study on erythropoietin and G-CSF: the liquid co-formulations were poorly stable under stress testing, and only a freeze-drying strategy achieved the goal, specifically lyophilization at pH 4.0 and reconstitution at pH 7.0. And even for a professionally developed fixed combination, it had to be specifically tested clinically whether the pharmacokinetics of both components are preserved; liraglutide exposure in the combination was measurably lower than alone, though still within the equivalence range.

This is exactly where the difference lies with a jointly freeze-dried blend like our blends: both components are converted together into the same solid and only dissolved together upon reconstitution. Peptides and proteins that have only limited stability in solution can be markedly more storage-stable in solid form, because the mobility of the molecules is severely restricted. This is not automatic, however: freeze-drying itself subjects the molecules to its own stresses during freezing and drying, which must be countered by suitably chosen protectants.

WOLVERINE (BPC-157 + TB-500)regeneration

The Wolverine Stack: BPC-157 + TB-500 in equal parts in one vial (50/50: 10mg = 5mg each, 20mg = 10mg each). The most researched healing peptide duo for tissue repair, tendon recovery, and systemic regeneration. Batch-specific Janoshik COA.

CJC-1295 (No-DAC)/Ipamorelingrowth

2-in-1 growth hormone blend: CJC-1295 no-DAC (Modified GRF 1-29, 5 mg) + Ipamorelin (5 mg) combined in one vial. The CJC-1295 component is the short-acting no-DAC variant (about 30 minute half-life), not the long-acting DAC form. Stimulates natural GH release through two different pathways for amplified, more physiological growth hormone pulses.

Semax/Selankcognitive

Pre-mixed combination of the two leading nootropic peptides in one vial. Semax boosts focus and BDNF, Selank reduces anxiety and enhances calm. Together they provide balanced cognitive enhancement for research.

What actually exists for the individual peptides

A sober finding to close, one that puts the whole discussion in perspective. For BPC-157, one of the most frequently combined peptides overall, a 2026 review states: no developed or validated pharmaceutical formulation exists, no biopharmaceutical classification, and no formal testing of excipient compatibility. So anyone reading a claim about the optimal solvent for BPC-157 is not reading validated pharmaceutics.

For the rest, it is no better. For retatrutide we found no experimentally determined isoelectric point and no substance-specific formulation pH from a peer-reviewed source. What exists are patent applications: a computationally predicted isoelectric point of about 3.93, meaning a calculation and not a measurement, and pH ranges claimed for the entire drug class including retatrutide. Everything else comes via class analogy to the approved GLP-1 preparations. For cagrilintide, no prescribing information exists; the classification relies on the related, approved amylin analog. For MOTS-c, SS-31, Selank, Semax, and KPV we found no formulation study addressing solubility, solvent choice, or pH stability. And for the commercially common no-DAC variant of CJC-1295, it holds that it is not the same molecule as the CJC-1295 of the original 2005 study, which carries an albumin-binding modification.

That is the honest starting position. It speaks neither for nor against mixing. It says that no one who makes a confident claim about it can substantiate it, ourselves included.

When the solution turns cloudy

If a single reconstituted solution turns milky, pH, concentration, or technique are the likely causes, not necessarily a defect. This case is different from the one addressed here and is covered in detail in our guide Why does my peptide turn cloudy, with customer photos, a list of causes, and a step-by-step approach. It also contains the documented table of which peptide is dissolved with which water. Anyone wanting to calculate the water volume for a target concentration can find that in the reconstitution calculator.

Frequently asked questions

Sources

1. Bacteriostatic Water for Injection, USP, prescribing information (Hospira). DailyMed
2. Chen BL, Wu X, Babuka SJ, Hora M. Solubility of recombinant human tissue factor pathway inhibitor. J Pharm Sci 1999;88(9):881-8. PMID 10479349. PubMed
3. Zhang L, Tan H, Fesinmeyer RM, et al. Antibody solubility behavior in monovalent salt solutions reveals specific anion effects at low ionic strength. J Pharm Sci 2012;101(3):965-77. PMID 22113783. PubMed
4. Alford JR, Kendrick BS, Carpenter JF, Randolph TW. High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. J Pharm Sci 2008;97(8):3005-21. PMID 17924426. PubMed
5. Lam XM, Patapoff TW, Nguyen TH. The effect of benzyl alcohol on recombinant human interferon-gamma. Pharm Res 1997;14(6):725-9. PMID 9210188. PubMed
6. Bis RL, Mallela KM. Antimicrobial preservatives induce aggregation of interferon alpha-2a. Int J Pharm 2014;472(1-2):356-61. PMID 24974985. PubMed
7. Li M, Falk BT, Lu X, et al. Molecular mechanism of antimicrobial excipient-induced aggregation in parenteral formulations of peptide therapeutics. Mol Pharm 2022;19(9):3267-78. PMID 35917158. PubMed
8. EGRIFTA WR (Tesamorelin), prescribing information. DailyMed
9. SEROSTIM (Somatropin), prescribing information. DailyMed
10. INCRELEX (Mecasermin), prescribing information: pH approx. 5.4, acetate buffer, 9 mg/ml benzyl alcohol. DailyMed
11. Svoboda ME, Van Wyk JJ, Klapper DG, et al. Purification of somatomedin-C from human plasma. Biochemistry 1980;19(4):790-7. PMID 7188854. PubMed
12. OZEMPIC (Semaglutide), prescribing information: pH approx. 7.4. DailyMed
13. MOUNJARO (Tirzepatide), prescribing information: pH 6.5 to 7.5. DailyMed. Same wording in ZEPBOUND (Tirzepatide): DailyMed
14. SYMLIN (Pramlintide), prescribing information: pH approx. 4.0. DailyMed
15. Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J 1981;199(3):649-56. PMID 7340824. PubMed
16. Conato C, Gavioli R, Guerrini R, et al. Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues. Biochim Biophys Acta 2001;1526(2):199-210. PMID 11325542. PubMed
17. Badenhorst T, Svirskis D, Wu Z. Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide. Pharm Dev Technol 2016;21(2):152-60. PMID 25384620. PubMed
18. Bodnár N, Várnagy K, Nagy L, et al. Ambivalent role of ascorbic acid in the metal-catalyzed oxidation of oligopeptides. J Inorg Biochem 2021;222:111510. PMID 34126320. PubMed
19. Torosantucci R, Sharov VS, van Beers M, et al. Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon beta-1a. Mol Pharm 2013;10(6):2311-22. PMID 23534382. PubMed
20. Bontreger LJ, Gallo AD, Moon J, et al. Intramolecular histidine cross-links formed via copper-catalyzed oxidation of histatin peptides. J Am Chem Soc 2025;147(15):12749-65. PMID 40197000. PubMed
21. Scherer TM, Leung S, Owyang L, Shire SJ. Issues and challenges of subvisible and submicron particulate analysis in protein solutions. AAPS J 2012;14(2):236-43. PMID 22391789. PubMed
22. Huang CT, Sharma D, Oma P, Krishnamurthy R. Quantitation of protein particles in parenteral solutions using micro-flow imaging. J Pharm Sci 2009;98(9):3058-71. PMID 18937372. PubMed
23. Staven V, Wang S, Grønlie I, Tho I. Development and evaluation of a test program for Y-site compatibility testing of total parenteral nutrition and intravenous drugs. Nutr J 2016;15:29. PMID 27000057. PubMed
24. Garreta Fontelles G, Padilla Castaño H, López López-Cepero M, et al. ICU Y-site compatibility at standardised infusion concentrations. Eur J Hosp Pharm 2025. PMID 41423337. PubMed
25. Boullata JI, Salman G, Mirtallo JM, et al. Parenteral nutrition compatibility and stability: practical considerations. Nutr Clin Pract 2024;39(5):1150-63. PMID 38994914. PubMed
26. LANTUS (Insulin glargine), prescribing information: pH approx. 4, mixing prohibited. DailyMed
27. HUMALOG (Insulin lispro), prescribing information: mixing only with NPH, sequence required, immediate injection. DailyMed
28. HUMULIN R (human insulin), prescribing information: mixing only with Humulin N. DailyMed
29. Adams PS, Haines-Nutt RF, Town R. Stability of insulin mixtures in disposable plastic insulin syringes. J Pharm Pharmacol 1987;39(3):158-63. PMID 2883277. PubMed
30. Giammaria D, Cinque B, Di Lodovico D, et al. Anti-vascular endothelial growth factor activity in the bevacizumab and triamcinolone acetonide combination for intravitreal use. Eur J Ophthalmol 2009;19(5):842-7. PMID 19787607. PubMed
31. XULTOPHY 100/3.6 (insulin degludec and liraglutide), prescribing information: pH approx. 8.15. DailyMed. For comparison, the two single-agent preparations: VICTOZA (liraglutide), pH approx. 8.15, DailyMed, and TRESIBA (insulin degludec), pH approx. 7.6, DailyMed
32. SOLIQUA 100/33 (insulin glargine and lixisenatide), prescribing information: pH approx. 4.5. DailyMed
33. European Medicines Agency. Xultophy: EPAR Public Assessment Report, EMA/CHMP/369341/2014. EMA
34. European Medicines Agency. Suliqua: EPAR Public Assessment Report, EMA/800280/2016. EMA
35. Krieg D, Svilenov H, Gitter JH, Winter G. Overcoming challenges in co-formulation of proteins with contradicting stability profiles: EPO plus G-CSF. Eur J Pharm Sci 2020;141:105073. PMID 31655209. PubMed
36. Kapitza C, Bode B, Ingwersen SH, et al. Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira. J Clin Pharmacol 2015;55(12):1369-77. PMID 25998481. PubMed
37. Izutsu KI. Applications of freezing and freeze-drying in pharmaceutical formulations. Adv Exp Med Biol 2018;1081:371-83. PMID 30288720. PubMed
38. Angkawinitwong U, Sharma G, Khaw PT, et al. Solid-state protein formulations. Ther Deliv 2015;6(1):59-82. PMID 25565441. PubMed
39. Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics 2026;18(5):625. PMID 42198317. PubMed
40. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146(7):3052-8. PMID 15817669. PubMed
41. Tobler SA, Holmes BW, Cromwell ME, Fernandez EJ. Benzyl alcohol-induced destabilization of interferon-gamma: a study by hydrogen-deuterium isotope exchange. J Pharm Sci 2004;93(6):1605-17. PMID 15124217. PubMed
42. Structural data from PubChem (NIH/NLM): BPC-157, CID 9941957 and Lys-Pro-Val (KPV), CID 125672. The analysis of side chains based on these molecular formulas and SMILES structures is our own, not a statement from a publication.
43. Our own corpus analysis of forum posts, collected on August 5, 2026 via the public Reddit archive Arctic Shift. All posts from five research subreddits were captured for the period August 5, 2025 to August 5, 2026 (95,262 posts), matched against 21 search terms related to mixing. Titles and post text were counted, not comments. Pair frequencies are joint mentions within a single post, not necessarily a dedicated mixing question; long compilation posts therefore contribute disproportionately many pairs. These numbers measure demand, not chemistry.
44. Kjeldsen BT, Hansen RRE, Christoffersen S (Novo Nordisk A/S). Patent application WO2024256632A1, filed June 14, 2024, published December 19, 2024: preserved liquid co-formulation of an amylin receptor agonist and a GLP-1 receptor agonist with hydroxypropyl cyclodextrin. Source of the computationally predicted isoelectric points (tirzepatide about 4.03, retatrutide about 3.93, amylin agonist 7.6 to 9.4). Google Patents

---

This article is intended exclusively for scientific research information purposes. It describes the behavior of peptides in solution and is not a usage, dosing, or injection guide.

Disclaimer: FOR RESEARCH USE ONLY. All products from PeptidesDirect are intended exclusively for in vitro research and laboratory use. Not for human consumption. Not for in vivo application. By purchasing, you confirm that the products are not intended for ingestion or any other use in humans.